Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6638957 | 1.00 | KMT2A (0.42) | KMT2AMEN1LPAR1SCN9ASMN1; SMN2 | |
| SCHEMBL6642563 | 0.90 | KMT2A (0.54) | KMT2AMEN1SCN9ASMN1; SMN2LMNA | |
| SCHEMBL6644456 | 0.87 | ACACB (0.40) | KMT2ASMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL6638257 | 0.85 | KMT2A (0.55) | KMT2AMEN1SCN9ASMN1; SMN2LMNA | |
| SCHEMBL6638254 | 0.85 | KMT2A (0.55) | KMT2AMEN1SCN9ASMN1; SMN2LMNA | |
| SCHEMBL6642320 | 0.83 | MAPT (0.43) | KMT2AMEN1SCN9ASMN1; SMN2POLB | |
| SCHEMBL6640226 | 0.81 | KMT2A (0.45) | KMT2AMEN1SCN9ASMN1; SMN2LMNA | |
| SCHEMBL6801757 | 0.81 | MAPT (0.45) | KMT2AMEN1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL6640582 | 0.79 | KMT2A (0.55) | KMT2AMEN1SMN1; SMN2LMNAPOLB | |
| SCHEMBL6069341 | 0.79 | KMT2A (0.47) | KMT2AMEN1SCN9APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686376-B2 | INHIBITING A RESISTANT NEOPLASM, OR A NEOPLASM SUSCEPTIBLE TO RESISTANCE IN A MAMMAL WHICH COMPRISES ADMINISTERING COMPOUND OF INVENTION | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-20030232854-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232854-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ABCC1, ABCB11, ABCB1 | KMT2A 4648/4885MEN1 2928/4885LPAR1 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.